A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A general term for various neoplastic diseases of the lymphoid tissue.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.

Intensive investigation in management of Hodgkin's disease. (1/3116)

Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for untreated disease apparently confined above the diaphragm. Abdominal disease cannot be confidently excluded on the basis of non-invasive investigation at presentation. Clinical assessment of splenic disease was unreliable unless gross splenomegaly was present. Pedal lymphography was accurate in assessing para-aortic and iliac disease but of no value in assessing other intra-abdominal lymph node involvement, including that of the mesenteric lymph node. Trephine bone marrow biopsy findings were normal in all patients before surgery, and only one patient was found to have diseased bone marrow by Stryker-saw biopsy at operation. Liver disease was identified at operation in nine patients, some of whom were asymptomatic with clinically undetectable splenic and nodal disease. Detailed clinical staging failed to detect disease in one-third of patients who underwent laparotomy. These studies show that if radiotherapy is to remain the treatment of choice for disease truly localised to lymph nodes a detailed staging procedure, including laparotomy and splenectomy, remains essential. The value of this potentially curative treatment is considerably diminished in the patient who has been inadequately staged.  (+info)

Prednisone in MOPP chemotherapy for Hodgkin's disease. (2/3116)

High remission rates have been produced by MOPP (mustine, vincristine, procarbazine, and prednisone) chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy. The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or without prednisone. In contrast to the findings of a British study, there were no significant differences in remission rates or length of remission between patients who had received prednisone and patients who had not. There were differences between the British prospective study and this retrospective one, but it is difficult to know what accounted for the substantial differences in the findings.  (+info)

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. (3/3116)

PURPOSE: Recent studies have suggested that lymphocyte-predominant Hodgkin's disease (LPHD) is both clinically and pathologically distinct from other forms of Hodgkin's disease, including classical Hodgkin's disease (CHD). However, large-scale clinical studies were lacking. This multicenter, retrospective study investigated the clinical characteristics and course of LPHD patients and lymphocyte-rich classical Hodgkin's disease (LRCHD) patients classified according to morphologic and immunophenotypic criteria. MATERIALS AND METHODS: Clinical data and biopsy material of all available cases initially submitted as LPHD were collected from 17 European and American centers, stained, and reclassified by expert pathologists. RESULTS: The 426 assessable cases were reclassified as LPHD (51%), LRCHD (27%), CHD (5%), non-Hodgkin's lymphoma (3%), and reactive lesion (3%); 11% of cases were not assessable. Patients with LPHD and LRCHD were predominantly male, with early-stage disease and few risk factors. Patients with LRCHD were significantly older. Survival and failure-free survival rates with adequate therapy were similar for patients with LPHD and LRCHD, and were stage-dependent and not significantly better than stage-comparable results for CHD (German trial data). Twenty-seven percent of relapsing LPHD patients had multiple relapses, which is significantly more than the 5% of relapsing LRCHD patients who had multiple relapses. Lymphocyte-predominant Hodgkin's disease patients had significantly superior survival after relapse compared with LRCHD or CHD patients; however, this was partly due to the younger average age of LPHD patients. CONCLUSION: The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients. Thorough staging is necessary to detect advanced disease in LPHD and LRCHD patients. The question of how to treat such patients, either by reducing treatment intensity or following a "watch and wait" approach, remains unanswered.  (+info)

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. (4/3116)

PURPOSE: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. RESULTS: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. CONCLUSION: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.  (+info)

Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. (5/3116)

BACKGROUND: Late complications after curative treatment of Hodgkin's disease are of special relevance because most of the cured are young adults. The aims of the present study were: (1) to compare health-related quality of life (HRQOL) in Hodgkin's disease (HD) survivors with normative data from the general Norwegian population and (2) to examine the relations between disease/treatment characteristics and HRQOL in the HD survivors. PATIENTS AND METHODS: 459 HD survivors aged 19-74 years (mean 44.0, SD 11.8) treated at the Norwegian Radium Hospital 1971-1991 were approached in 1994 and compared to norms from 2214 subjects approached in 1996. The norms are representative of the general Norwegian population. HRQOL was assessed by the Short Form 36 (SF-36), which measures HRQOL in eight separate scales (0 = worst health state, 100 = best health state). RESULTS: The HD survivors had lower scores than the normal controls on all scales after adjustment for age, gender and educational levels. Statistically significant differences (P < 0.01) were found in general health (10.4), physical functioning (6.1), role limitations (physical, 9.3), physical functioning (3.6) and in vitality (4.7). Patients with disease stage IB-IIB had the lowest scores on all scales. The differences in relation to stage/substage reached statistical significance (P < 0.01) in physical functioning and in role limitations (physical). Time since diagnosis, types of primary treatment or having relapsed were not associated with statistically significant differences in HRQOL. CONCLUSION: Long-term HD survivors have poorer HRQOL, primarily in physical health, than the general Norwegian population.  (+info)

Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. (6/3116)

BACKGROUND: The purpose of this study was to elucidate the clinical reliability of immunoscintigraphy (IS) to detect infiltration of the bone marrow in patients with malignant lymphoma. PATIENTS AND METHODS: Whole body IS was performed in 103 patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) using Tc-99m labelled anti-NCA-95 which allows visualization of the granulopoietic bone marrow. Of these, 52% were studied prior to any therapy. Findings were compared to posterior iliac crest biopsy as well as MRI and/or follow-up examination. Criteria of marrow infiltration were a positive biopsy, positive follow-up, or positive results of MRI. RESULTS: Comparison of IS and biospy revealed concordant findings in 69 and discordant findings in 34 of 103 patients. Of the 34 patients with discordant results, IS showed lesions suspicious of bone marrow infiltration in 29 patients despite normal biopsy findings. When follow-up and additional examinations were taken into consideration, 10 patients remained with probably false positive and five with false negative IS findings. IS proved to be highly sensitive and specific in patients with HD (100% and 84%, respectively) and high-grade NHL (93% and 84%, respectively). Moderate sensitivity (60%) was found in low-grade NHL. This was possibly due to false negative IS in three to five patients with chemotherapy in contrast to one of five false negative results in patients without chemotherapy. CONCLUSION: Bone marrow scintigraphy using antigranulocyte antibodies is highly sensitive in HD and high-grade NHL. Positive findings in IS subsequent to a negative biopsy should be followed by guided re-biopsy or MRI.  (+info)

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. (7/3116)

PURPOSE: Hodgkin's disease patients who never achieve complete remission with conventional chemotherapy (i.e., those with primary induction failure) have a poor prognosis. Some subjects who receive high-dose therapy with autologous hematopoietic progenitor-cell infusion experience prolonged progression-free survival. PATIENTS AND METHODS: Detailed records from the Autologous Blood and Marrow Transplant Registry (ABMTR) on 122 Hodgkin's disease patients who failed to achieve complete remission after one or more conventional therapy regimens and subsequently received an autotransplant between 1989 and 1995 were reviewed. RESULTS: Median age was 27 years (range, 7 to 57 years). Median time from diagnosis to transplantation was 14 months (range, 5 to 38 months). Most patients received high-dose chemotherapy without radiation for pretransplantation conditioning (n = 107). The regimen most frequently used was cyclophosphamide, carmustine, and etoposide (n = 47). Fifteen patients received total-body irradiation (n = 15). The graft consisted of bone marrow (n = 86), blood stem cells (n = 25), or both (n = 11). The 100-day mortality was 12% (95% confidence interval, 7% to 19%). Sixty patients (50%) were considered to have achieved complete remission after autotransplantation; 37 of these had negative imaging studies, whereas scan abnormalities of unknown significance persisted in 23 patients. Twenty-seven patients (22%) had no response or progressive disease after transplantation. Probabilities of progression-free and overall survival at 3 years were 38% (95% confidence interval, 28% to 48%) and 50% (95% confidence interval, 39% to 60%), respectively. In multivariate analysis, "B" symptoms at diagnosis and poor performance score at transplantation were adverse prognostic factors for outcome. CONCLUSION: Autotransplants should be considered for patients with Hodgkin's disease who do not achieve complete remission with conventional therapy.  (+info)

Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates. (8/3116)

The blastogenic response to autologous blood lymphocytes to whole-cell suspensions and to homogenates obtained from malignant lymphoma tissue has been investigated. Spleens were obtained from patients in whom laparotomy was performed for staging of malignant lymphoma. Cell suspensions prepared from tumour nodules were treated with mitomycin C and allowed to react with separated autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured by liquid scintillation counting after exposure to 3H-TdR. Cultures were also prepared in which autologous lymphocytes were treated with spleen tumour homogenate. Control experiments used spleens from staging procedures in which no tumour deposits were present, and normal spleens removed incidentally during other operations. In the controls, the uptake of TdR was never more than twice that of unstimulated lymphocytes. Greater degrees of lymphocyte stimulation were seen in 6 out of 14 patients, using whole tumour cells, and in 7 out of 16 patients, using tumour homogenates. The results indicate an antigenic difference between tumour and host cells, and suggest that lymphocytes can react to a tumour-associated antigen.  (+info)

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

Symptoms of EBV infection can vary widely, ranging from asymptomatic to severe, and may include:

* Fatigue
* Fever
* Sore throat
* Swollen lymph nodes in the neck and armpits
* Swollen liver or spleen
* Rash
* Headaches
* Muscle weakness

In some cases, EBV can lead to more serious complications such as infectious mononucleosis (IM), also known as glandular fever, which can cause:

* Enlarged liver and spleen
* Splenomegaly (enlargement of the spleen)
* Hepatomegaly (enlargement of the liver)
* Thrombocytopenia (low platelet count)
* Anemia (low red blood cell count)
* Leukopenia (low white blood cell count)

EBV is also associated with an increased risk of developing certain types of cancer, including Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal carcinoma.

There is no specific treatment for EBV infections, and most cases resolve on their own within a few weeks. Antiviral medications may be prescribed in severe cases or to prevent complications. Rest, hydration, and over-the-counter pain relief medication can help alleviate symptoms.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

Previous articleNeoplastic Cells
Next articleNephrocalcinosis

DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.

The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Night sweats
* Weight loss
* Abdominal pain or discomfort
* Itching

The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

The inclusion of "bulky disease" is signified by "X". Stage 1 Hodgkin lymphoma Stage 2 Hodgkin lymphoma Stage 3 Hodgkin ... "A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease". The ... In 2017, approximately 990 Canadians will be diagnosed with Hodgkin lymphoma, and 140 will die of the disease. Hodgkin lymphoma ... Hodgkin lymphoma at Curlie Hodgkin Lymphoma at American Cancer Society Hodgkin Lymphoma at the American National Cancer ...
... formerly designated Hodgkin's disease) and non-Hodgkin lymphoma (abbreviated NHL). It was initially developed for Hodgkin's, ... Mauch P, Armitage J, Diehl V, Hoppe R, Weiss L (1999). Hodgkin's Disease. Lippincott Williams & Wilkins. pp. 223-228. ISBN 978- ... Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (November 1971). "Report of the Committee on Hodgkin's Disease ... Rosenberg SA (June 1966). "Report of the committee on the staging of Hodgkin's disease". Cancer Research. 26 (6 Part 1): 1310. ...
"Every student and every doctor knows that cases of Hodgkin's disease may show a fever that is high for one week and low for the ... Piccin p.48 Mauch, Peter; James Armitage; Volker Diehl; Richard Hoppe; Laurence Weiss (1999). Hodgkin's Disease. Lippincott ... Ree, HJ (1987). "Stromal macrophage-histiocytes in Hodgkin's disease. Their relation to fever". Cancer. 60 (1479): 1479-84. doi ... To count as Pel-Ebstein fever diagnostic workup for Hodgkin's lymphoma would be required as well if that diagnosis was not ...
Hodgkin lymphoma typically is treated with radiotherapy alone, as long as it is localized. Advanced Hodgkin disease requires ... Hodgkin lymphoma Classical Hodgkin lymphomas: Nodular sclerosis form of Hodgkin lymphoma Most common type of Hodgkin lymphoma ... A division into Hodgkin and non-Hodgkin lymphomas is used in several of the older classification systems. A Hodgkin lymphoma is ... Non-Hodgkin lymphomas, which are defined as being all lymphomas except Hodgkin lymphoma, are more common than Hodgkin lymphoma ...
Mauch, Peter; James Armitage; Volker Diehl; Richard Hoppe; Laurence Weiss (1999). Hodgkin's Disease. Lippincott Williams & ... In 1880, Pel was appointed Lecturer in Contagious Diseases and Physiological Diagnostics. In 1883 he became a full Professor of ... or that of a separate disease (Ebstein). Pel also discovered what came to be called "Pel's crisis," defined as "Ocular crises ... Dutch infectious disease physicians, People from Smallingerland, Leiden University alumni, University of Amsterdam faculty). ...
... non-Hodgkin lymphoma (NHL); Hodgkin disease; Chronic lymphocytic leukemia (CLL); including hairy cell leukemia and other ... Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, chloracne, porphyria cutanea tarda, peripheral neuropathy, ... On 26 January 2012, the U.S. Center For Disease Control's Agency for Toxic Substances and Disease Registry challenged this with ... This list now includes B cell leukemias, such as hairy cell leukemia, Parkinson's disease and ischemic heart disease, these ...
Mauch, Peter; James Armitage; Volker Diehl; Richard Hoppe; Laurence Weiss (1999). Hodgkin's Disease. Lippincott Williams & ... Nodular sclerosis (or "NSHL") is a form of Hodgkin's lymphoma that is the most common subtype of HL in developed countries. It ... November 2007). "A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell- ... hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy". Eur. J. Haematol. 79 (5): 455-61. doi ...
Stier JR, Vasquez RJ (2015). "Lymphocyte-Predominant Hodgkin's Disease in Children: A Case Study and Review of the Literature ... Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a slow-growing CD20 positive form of Hodgkin lymphoma, a cancer of ... NLPHL is an uncommon sub-type of Hodgkin lymphoma, making up 5-10% of Hodgkin lymphomas. It is distinguished from classic ... 2014). "Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair ...
"Hodgkin's Disease - Staging". oncologychannel. Archived from the original on 2008-10-25. Retrieved 2010-10-14. "Breast Cancer ... Systems of staging may differ between diseases or specific manifestations of a disease. Lymphoma: most use Ann Arbor staging ... in Hodgkin's Disease, Stage II indicates affected lymph nodes on only one side of the diaphragm, whereas Stage III indicates ... Because of its high sensitivity, RT-PCR screening for GCC greatly reduces underestimation of disease stage. Researchers hope ...
ISBN 978-0-8147-3562-6. L'esperance ES (January 1931). "Studies in Hodgkin's Disease". Annals of Surgery. 93 (1): 162-168. doi: ... List of oncogenic bacteria Infectious causes of cancer List of human diseases associated with infectious pathogens Oncovirus ... "An experimental biologic approach to the treatment of neoplastic disease; determination of actinomycin in urine and cultures as ... management and pathogenesis of the disease". Microscopy Research and Technique. 48 (6): 349-356. doi:10.1002/(SICI)1097-0029( ...
He trained as a pathologist and performed his PhD research on the Immunopathology of Hodgkin's Disease at the Department of ... "Immunopathology of Hodgkin's disease". rug.nl. Retrieved January 25, 2021. "Sibrandes Poppema". Google Scolar. Retrieved ...
Thomas Hodgkin (1798-1866), English physician & pathologist; eponymist of Hodgkin's disease. Friedrich Albin Hoffmann (1843- ... William Boog Leishman (1865-1926), English authority on the pathology of human parasitic diseases (see leishmaniasis) George ... Adolf Weil (1848-1916), German physician and pathologist (see Weil's disease). Ronald S. Weinstein (1938-2021), American ... Ludvig Hektoen (1863-1951), American researcher on pathology of infectious diseases. Arnold Ludwig Gotthilf Heller (1840-1913 ...
ISBN 978-1-4832-1841-0. G. W. Richter; Kim Solez (22 October 2013). Progress in Hodgkin's Disease. Elsevier Science. ISBN 978-1 ... and Diseases. Elsevier Science. ISBN 978-1-4832-8230-5. Kim Solez (1994). International Review of Experimental Pathology: vol. ...
Bonadonna, G.; Fossati, V.; De Lena, M. (1978). "MOPP versus MOPP plus ABVD in Stage IV Hodgkin's disease". Proc. Am. Assoc. ... Prior to the mid-1960s, advanced-stage Hodgkin disease was treated with single-agent chemotherapy, with fairly dismal long-term ... May 1980). "Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the ... One study found bleomycin lung damage in 18% of patients receiving ABVD for Hodgkin disease. Retrospective analyses have ...
He was a graduate of Yale University and Johns Hopkins University who would suffer from Hodgkin's Disease. After learning of ... Hoster became a charter member of the Hodgkin's Disease Research Foundation in New York City, serving as the original President ... "Radiotherapy of Hodgkin's disease". Proc R Soc Med. 65 (12): 1109-10. PMC 1644412. PMID 4631266. The National Cyclopaedia of ... There he focused on research of the disease at Ohio State University. He became a professor of medicine and eventually an ...
... relapsed/refractory Hodgkin's disease). In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, ... T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, ...
... interstitial lung disease (e.g., bleomycin) and occasionally secondary neoplasm (e.g., MOPP therapy for Hodgkin's disease). ... A disease resulting from aggressive chemotherapy". Diseases of the Colon and Rectum. 32 (3): 206-9. doi:10.1007/BF02554529. ... including Hodgkin's disease) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing ... Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (9): e162-e193. doi: ...
Synge suffered from Hodgkin's disease. He died aged 37 from Hodgkin's-related cancer, while writing what became Deirdre of the ... In 1897, Synge suffered his first attack of Hodgkin's, after which an enlarged gland was removed from his neck. He visited Lady ... Synge died from Hodgkin lymphoma at the Elpis Nursing Home in Dublin on 24 March 1909, aged 37, and was buried in Mount Jerome ... Deaths from Hodgkin lymphoma, Deaths from cancer in the Republic of Ireland, Alumni of Trinity College Dublin, People from ...
Sagar, Tenali G.; Chandra, Anita (2005). "Progress in Hodgkin's Disease Research". Trends in Hodgkin's Disease Research. Nova ... Decadence and Disease in the Russian Fin de Siècle: Neurasthenia in the Life and Work of Leonid Andreev (Oxford University ...
"Arlen Specter's Hodgkin's disease returns". CNN. April 15, 2008. Archived from the original on April 25, 2009. Retrieved April ... "significantly less advanced than his Hodgkin's disease when it was originally diagnosed in 2005." He underwent a second round ... Diagnosed with Hodgkin's lymphoma in early 2005, he continued his work in the Senate while undergoing chemotherapy. He died ... He was diagnosed six weeks earlier with a new form of the disease. On September 7, 2012, he was released from a Philadelphia ...
Rivas C, Oliva H (1974). "Nuclear bodies in Hodgkin's disease". Pathologia Europaea. 9 (4): 297-301. PMID 4457783. Tani E, ... CS1: long volume value, Articles with short description, Short description is different from Wikidata, Autoimmune diseases, ... but appear also to be elevated in many autoimmune and cancerous diseases. Nuclear dots are metabolically stable and resistant ... functional roles and cellular signalling in health and disease". Cellular Signalling. 16 (10): 1085-104. doi:10.1016/j.cellsig. ...
"Hodgkin's disease fatal to Vellone." St. Petersburg Times, Aug. 23, 1977". Pro Football Reference: Jim Vellone (Articles with ... Jim Vellone abruptly retired from the NFL in 1971 when he discovered he had Hodgkin's lymphoma. He spent the final six years of ... Although managing to live a normal life for some time, Vellone finally succumbed to the cancerous disease on August 21, 1977, a ... Vellone's career and life were cut short due to Hodgkin's lymphoma. Before he joined the pro leagues, Vellone played college ...
Some malignancies that have spread to involve the bone marrow, such as leukemia or advanced Hodgkin's disease, also cause ... Weiss RB, Brunning RD, Kennedy BJ (December 1975). "Hodgkin's disease in the bone marrow". Cancer. 36 (6): 2077-83. doi:10.1002 ... Faguet GB (October 1975). "Quantitation of immunocompetence in Hodgkin's disease". The Journal of Clinical Investigation. 56 (4 ... The SARS disease caused lymphocytopenia. Among patients with laboratory-confirmed COVID-19 in Wuhan China through January 29th ...
However, before the start of the 2003 season, he learned he had Hodgkin's disease, and he was forced to sit the season out. ... "Doctors discover Hodgkin's disease has returned". ESPN. May 6, 2005. Retrieved July 22, 2011. https://www.tmz.com/2010/08/10/ ... Fields returned to play in 2004 Fields learned before the start of the 2005 season that his Hodgkin's had returned, and so he ... Louis Rams, and the Carolina Panthers before missing the 2005 NFL season due to being diagnosed with Hodgkin lymphoma for the ...
Hors J, Dausset J (1983). "HLA and susceptibility to Hodgkin's disease". Immunol. Rev. 70: 167-92. doi:10.1111/j.1600-065X.1983 ... 1977). "HLA and MLC typing in patients with Hodgkin's disease". Prog. Clin. Biol. Res. 16: 217-27. PMID 143667. Middleton, D.; ... Within the early studies, A1 was found associate with or protected against some infectious diseases. Some diseases found ... Most of the disease risk conferred by A*01:01 are represented by either A1 serotype risks, or A1-B8 serotype risk (In Europe A1 ...
Tula died of Hodgkin's Disease in 1963. He married Rina Balter in 1964. They had no children together but were active in the ... Youngner survived many infections as a young child which left him with a lifelong interest in infectious disease. After ... and persistent newcastle disease virus. Youngner is responsible for the first equine influenza vaccine, based upon cold-adapted ... Journal of Infectious Diseases. 131 (4): 467-473. doi:10.1093/infdis/131.4.467. ISSN 0022-1899. PMID 163873. Youngner, J. S.; ...
"Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer ... The two also collaborated to create the MOPP regimen for Hodgkin's lymphoma. As former chair of the Lymphoma Committee of the ... His research career spans many decades as well as several areas of therapeutic agents for the treatment of malignant diseases. ...
CD15 and CD30 : used for Hodgkin's disease. Alpha fetoprotein: for yolk sac tumors and hepatocellular carcinoma. CD117 (KIT): ... a disease characterized by the formation of a specific abnormal tyrosine kinase. Imitanib has proven effective in tumors that ...
Her dissertation was titled CD40 signaling Hodgkin's disease. She came to the National Cancer Institute (NCI) as a postdoctoral ... Annunziata, Christina Messineo (2000). CD40 signaling Hodgkin's disease (Ph.D. thesis). Georgetown University. OCLC 45954730. " ...
He died of Hodgkin's disease in 1989. He was inducted in the Tennessee Sports Hall of Fame in 1976. The Joe C. Davis Professor ... Deaths from Hodgkin lymphoma, Deaths from cancer in Tennessee). ...
Ian Lindsay died of Hodgkin's Disease in Bangour Hospital in 1966. At his express wish his ashes were scattered from a boat ...
Armfield died of the disease on 22 January 2018 in Blackpool, at the age of 82. Armfield was inducted into Blackpool's Hall of ... On 11 May 2007, he announced on BBC Radio Lancashire that he had been undergoing chemotherapy treatment for non-Hodgkin ...
... is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin ... In the United States, rituximab is indicated to treat: non-Hodgkin lymphoma (NHL) chronic lymphocytic leukemia (CLL) rheumatoid ...
Prince Bernhard has been receiving treatment for Crohn's disease since 2002. In 2013, he was diagnosed with Non-Hodgkin ...
... active systemic autoimmune disease, interstitial lung disease, prior pneumonia, and people with a history of severe reaction to ... the treatment of adults with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell ... "Pembrolizumab (Keytruda) for classical Hodgkin lymphoma". U.S. Food and Drug Administration (FDA). 14 March 2017. Archived from ... "FDA Approves Pembrolizumab for Advanced Cervical Cancer with Disease Progression During or After Chemotherapy". ASCO. 12 June ...
"Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease". The Journal of ... The expression of galectin-9 has been detected on various hematological malignancies, such as CLL, MDS, Hodgkin and Non-Hodgkin ... "A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells". British ...
2018,Genomic Analyses of Human European Diversity at the Southwestern Edge: Isolation, African Influence and Disease ... Paris 1999 Hodgkin, Thomas (1848). On the Ancient Inhabitants of the Canary Islands (PDF). Journal of the Ethnological Society ... that intended to know the relationship of Canarian genetic diversity with the more prevalent complex diseases in the ...
In most cases, patients with heart metastases have advanced tumour disease, with the heart being only one of the many places ... Most cases were angiosarcomas (27.3%) with an incidence of 0.107 per 1,000,000 person-years and Non- Hodgkin's lymphomas [NHL ... These symptoms mimic symptoms of other heart diseases, which can make diagnosis difficult.[citation needed] In most cases, the ... At that stage of the disease, the patients will have already undergone extensive chemotherapy, radiation therapy or surgical ...
Hajjar, Reem; Hodgkin, Toby (9 February 2007). "The use of wild relatives in crop improvement: a survey of developments over ... difference in disease susceptibility There are uses of coexisting wild ancestors and their domestic counterparts. The existence ...
Hodgkin, Jonathan (2005). "Introduction to genetics and genomics". WormBook. doi:10.1895/wormbook.1.17.1. Greenwald, Iva (2005 ... Post-embryonic development Sex-determination systems The germ line Neurobiology and behavior Evolution and ecology Disease ...
During the 1940s he, with Frank Fletcher, did pioneering research on chemotherapy for leukæmia, Hodgkin's disease, and ... Hodgkin's disease, and polycythæmia vera: Report on eighteen cases". The Lancet. 250 (6476): 540-545. doi:10.1016/S0140-6736(47 ...
Excluded diseases include: Hodgkin's disease, hairy cell leukaemia, chronic lymphatic leukaemia (CLL), malignant melanoma and ... Other compensable diseases include cataracts and leukaemias (with two exceptions). Some diseases are excluded on the basis that ... "CSRLD: The Compensation Scheme for Radiation Linked Diseases - Q & A". www.csrld.org.uk. Archived from the original on 2016-06- ... "CSRLD: The Compensation Scheme for Radiation Linked Diseases - Scheme history". www.csrld.org.uk. Archived from the original on ...
King, Richard (1867). "Obituary of Thomas Hodgkin, M.D.". Transactions of the Ethnological Society of London. 5: 341-345. JSTOR ... Deaths from lung disease). ...
... and a type of lymphoproliferative disease which shares clinical characteristics with the indolent non-Hodgkin lymphomas. It is ... Notable victims of the disease include dancer/choreographer Gower Champion, who died of the disease in 1980, aged 61; and ... While the disease is incurable, it is treatable. Because of its indolent nature, many patients are able to lead active lives, ... But on occasion, the disease can be fatal, as it was to the French president Georges Pompidou, who died in office in 1974. ...
LLS also advocates for public policy positions that accelerate progress toward cures for leukemia, Hodgkin and non-Hodgkin ... Acute myeloid leukemia (AML) is a rapidly progressing disease that remains one of the most deadly blood cancers, killing more ... The LLS's mission is to cure leukemia, lymphoma, Hodgkin's lymphoma and myeloma, and improve the quality of life of patients ... At 38 years old, he was diagnosed with Hodgkin's lymphoma. Past national spokespeople include Tina Fey in 2009 and Cynthia ...
Sloane, who suffers from Hodgkin's disease, is living on borrowed time though. Viki actually marries him while he is in the ...
... itself more common in diseases such as systemic lupus erythematosus, rheumatoid arthritis, Hodgkin's lymphoma, and chronic ... and Eclampsia Hemolytic disease of the newborn is an autoimmune disease resulting from the mother's antibodies crossing the ... cold agglutinin disease) or permanent factors as in autoimmune diseases like autoimmune hemolytic anemia ( ... Hemolytic crises are a major concern with sickle-cell disease and G6PD deficiency. Paxillus involutus ingestion can cause ...
... he would not have been taken to the hospital and diagnosed as having his disease in time. In November 2008, a video spread ... it was announced on WWE.com that Toombs had Hodgkin's lymphoma; he finished radiation therapy on January 15, 2007. This was ...
... with symptoms of tuberculosis but both the consultant physician and the consultant surgeon took the view that Hodgkin's disease ...
Lewis Rowland, Leading Neurologist on Nerve and Muscle Diseases, Dies at 91 The Little-Known Statistician Who Taught Us to ... Sir Howard Hodgkin, 84, British painter and printmaker. Keith Holliday, 82, British rugby league player (Wakefield Trinity). ... Daisuke Satō, 52, Japanese game designer, novelist, and manga writer (Highschool of the Dead), ischemic heart disease. Helena ... Penelope Reed Doob, 73, American academic, Parkinson's disease. Jean-Claude Étienne, 75, French politician. Garrett G. Fagan, ...
Petersburg, Florida on March 12, 1938 from complications related to Hodgkin's disease. Russell was a charismatic figure, but ... died from heart disease at 2:30 o'clock this afternoon on an Atchison, Topeka Santa Fe train, en route from Los Angeles to New ...
A prion disease called kuru has been traced to this. Brain-computer interface Central nervous system disease List of ... Hodgkin J (2001). "Caenorhabditis elegans". In Brenner S, Miller JH (eds.). Encyclopedia of Genetics. Elsevier. pp. 251-256. ... The most important that are covered in the human brain article are brain disease and the effects of brain damage. The shape and ... All these things we endure from the brain, when it is not healthy... On the Sacred Disease, attributed to Hippocrates The Roman ...
Acting Director of the National Center for Infectious Diseases (NCID), Centers for Disease Control (CDC) Maxine Frank Singer - ... Thwaite, Ann (25 March 2015). "Marni Hodgkin obituary". The Guardian. Retrieved 3 May 2015. Anthony, Ted (2020-04-03). "Anick ... sociologist and author Marni Hodgkin, children's book editor tech Anick Jesdanun (1991), technology reporter, editor, and the ...
ISBN 978-0-85186-333-7. "Dorothy Crowfoot Hodgkin, OM". Archived from the original on 2012-01-12. Retrieved 2012-01-13. Fermi, ... of the behavior of exhaled respiratory droplets and their influence on the transmission of infectious respiratory diseases. ...
... or the Reed-Sternberg cells associated with Hodgkin disease. As detected by immunostaining methods, the malignant cells ... As their disease progresses, however, individuals with the classical effusion-form of PEL may develop extracavitary tumors and ... In this study, patients with advanced Ann Arbor Stage III or IV disease had a particularly poor survival rate at 1 year of 25 ... Individuals diagnosed with PEL most commonly (>33% of all cases) present with advanced Stage III or IV disease. They are ...
... is under the category of non-Hodgkin lymphoma. Mature T-cell lymphomas account for 10% to 15% of all ... Bone marrow biopsy is used to show the extent of disease, known as staging in pathology. The process takes about 10-15 minutes ... Biopsy is a common medical test involving removal of a patient's tissues or cells to determine the presence of disease via ... The following tests are performed to confirm the presence of lymphoma cells and the severity of disease. Mature T-cell lymphoma ...
2010 update by the infectious diseases society of america". Clinical Infectious Diseases. 52 (4): e56-93. doi:10.1093/cid/ ... August 2016). "Mapping the Epidemiology of Kaposi Sarcoma and Non-Hodgkin Lymphoma Among Children in Sub-Saharan Africa: A ... Disease Primers. 5 (1): 9. doi:10.1038/s41572-019-0060-9. PMC 6685213. PMID 30705286. Africa CW, Nel J, Stemmet M (July 2014 ... Pan SW, Shu CC, Feng JY, Su WJ (June 2020). "Treatment for Mycobacterium avium complex lung disease". Journal of the Formosan ...
Hodgkin AL, Huxley AF (August 1952). "A quantitative description of membrane current and its application to conduction and ... Berger analyzed the interrelation of alternations in his EEG wave diagrams with brain diseases. EEGs permitted completely new ... interface between a recording electrode and the electrolytic solution surrounding neurons has been modelled using the Hodgkin- ...
He died on January 18, 1981, in Washington, D.C., of complications from mycosis fungoides, a non-Hodgkin's lymphoma. He is ... she had been suffering from Alzheimer's disease. She was buried next to her husband. Wilson's professional papers are at ... Deaths from non-Hodgkin lymphoma, People from Galesburg, Illinois, Pulitzer Prize for National Reporting winners, 1905 births, ...
Dr Thomas Hodgkin first described Hodgkin disease in 1832. ... Hodgkin disease is a cancer of the lymph system (a lymphoma) ... encoded search term (Thoracic Hodgkin Disease (Lymphoma) Imaging) and Thoracic Hodgkin Disease (Lymphoma) Imaging What to Read ... Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkins disease and non-Hodgkins ... recurrent Hodgkin disease may appear in the absence of adenopathy (especially in nodular sclerosing Hodgkin disease). ...
Hodgkin lymphoma is a type of lymphoma, cancer of the lymph system. It is serious but can usually be cured if found and treated ... What is Hodgkin lymphoma? Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system ... Stages of Adult Hodgkin Lymphoma (National Cancer Institute) Also in Spanish * Stages of Childhood Hodgkin Lymphoma (National ... Key Statistics for Hodgkin Lymphoma (American Cancer Society) Also in Spanish * Whats New In Hodgkin Lymphoma Research? ( ...
Hodgkin Disease: Jacquelines Story. Before my diagnosis I was your typical 22-year-old. My priorities were boys, drinking and ... I was among the 15 percent of patients with this disease for whom chemo, alone, didnt work. That was the first time my doctor ... The last step before my bone marrow transplant would be radiation to get rid of the remaining disease. I was thrilled, but what ... My mom found a clinical trial at Memorial Sloan Kettering for patients with Hodgkin lymphoma. There was only one spot left in ...
Because of certain characteristics it is no longer classified as a form of Hodgkins Disease ... Nodular lymphocyte predominant Hodgkin lymphoma is a form of Hodgkins lymphoma. ... Hodgkin Lymphoma. Hodgkins Disease Hurthle Cell Adenoma. Immunoproliferative Diseases. Insulinoma. Kaposis Sarcoma. ... Nodular Lymphocyte Predominant Hodgkin Lymphoma. Nodular Melanoma. Nodular Sclerosis Classical Hodgkin Lymphoma. Non-Hodgkins ...
Epidemiology of Hodgkins disease: a review. Hematol Oncol. 2004;22:11-26. DOIPubMedGoogle Scholar ... Hodgkin Lymphoma after Disseminated Mycobacterium genavense Infection, Germany. Emerging Infectious Diseases. 2022;28(7):1506- ... Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.; ATS Mycobacterial Diseases Subcommittee; ... Molecular biology of Hodgkin lymphoma. Leukemia. 2021;35:968-81. DOIPubMedGoogle Scholar ...
title = "Immunotherapy for Hodgkins disease",. abstract = "EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S ... EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S) cells of about 40% of patients with Hodgkins Disease (HD) ... N2 - EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S) cells of about 40% of patients with Hodgkins Disease ... AB - EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S) cells of about 40% of patients with Hodgkins Disease ...
FDA Approves Adcetris for Refractory Hodgkins Disease and a Rare T-Cell Lymphoma. August 22, 2011. September 6, 2011. Elaine ... Seattle Genetics disclosed that the annual cost for Adcetris, which the FDA approved late last week to combat Hodgkins disease ... There are nearly 9,000 cases of Hodgkins lymphoma (a related condition, usually of B cells) each year in the U.S. Only a small ... Approximately 66,000 people receive a diagnosis of non-Hodgkins lymphoma (NHL) every year in the U.S.; if a third of the ...
Non-Hodgkin answers are found in the Diseases and Disorders powered by Unbound Medicine. Available for iPhone, iPad, Android, ... Lymphoma, Non-Hodgkin [Internet]. In: Diseases and Disorders. F.A. Davis Company; 2019. [cited 2023 June 03]. Available from: ... Sommers, Marilyn Sawyer.. "Lymphoma, Non-Hodgkin." Diseases and Disorders, 6th ed., F.A. Davis Company, 2019. Nursing Central, ... nursing.unboundmedicine.com/nursingcentral/view/Diseases-and-Disorders/73653/all/Lymphoma__Non_Hodgkin PB - F.A. Davis Company ...
Hodgkins cells occur in diseases other than Hodgkins disease ... 1) if Reed-Sternberg is mentioned, think Hodgkins 2) if ... 1) Reed-Sternberg cells - have binucleated, mirror-imge morphology (most common in mixed cellularity variant) 2) Hodgkins ... Details of surgical procedures, pathophysiology, signs and symptoms, and treatment of medical diseases,medical and surgical ... question mentions a 21 year-old male with fevers and enlarged but nontender neck nodes, think Hodgkins 3) 20-40% of Hodgkins ...
... Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019 ... Linfoma não Hodgkin/complicações; Linfoma não Hodgkin/genética; Linfoma Difuso de Grandes Células B/diagnóstico; Linfoma Difuso ... Non-Hodgkin lymphoma (NHL) is the eleventh leading cause of cancer-related death in the world. Diffuse large B-cell lymphoma ( ...
Hodgkin Disease. Disease. Neoplasms by Histologic Type. Neoplasms. Lymphoproliferative Disorders. Lymphatic Diseases. ... Condition or disease Intervention/treatment Phase Hodgkin Lymphoma Coexisting Medical Conditions Drug: Nivolumab Drug: ... Any serious active disease, severe cardio-pulmonary, or metabolic disease interfering with normal application of protocol ... Subjects with active infectious disease. *Subjects with active, known or suspected autoimmune disease. Are permitted to enroll ...
Cynthia G. Whitney, MD, Matt Moore, MD, Tamara Pilishvili, MPH, Respiratory Diseases Br, Div of Bacterial Diseases, National ... Centers for Disease Control and Prevention 1600 Clifton Road Atlanta, GA 30329-4027, USA. 800-CDC-INFO (800-232-4636) TTY: (888 ... Diseases requiring treatment with immunosuppressive drugs, including long-term systemic corticosteroids and radiation therapy. ... Including chronic obstructive pulmonary disease, emphysema, and asthma.. ¶ Includes B- (humoral) or T-lymphocyte deficiency, ...
Treatment of hyperhidrosis palmaris (sweaty hands); a familial disease in Japanese. Hawaii Med J. 1957 Mar-Apr. 16(4):381-7. [ ...
Hodgkin Lymphoma Treatment: Boosting New Options for Young People with Advanced Disease ...
... before 1885 and misdiagnosed it as Addison disease, the first documented case of acanthosis nigricans was in 1889 in Germany as ... Patients should be instructed that acanthosis nigricans is not a skin disease per se, but rather a sign of an underlying ... Although Addison may have seen a case of acanthosis nigricans (AN) before 1885 and misdiagnosed it as Addison disease, the ... Gönül M, Kiliç A, Cakmak SK, Gül U, Ekiz OD, Ergül G. Juvenile generalized acanthosis nigricans without any systemic disease. ...
Hodgkin Disease / drug therapy * Humans * Leukemia, Myeloid / etiology* * Leukemia, Myeloid / genetics * Leukemia, Myeloid / ... appropriate for de novo AML patients with similar disease characteristics. Allogeneic hematopoietic cell transplantation can ...
Hodgkins lymphoma (HL) is now a highly curable disease, with an improving 5-year survival rate that has now reached 86%. At ... Gebert C, Hardes J, Ahrens H, Buerger H, Winkelmann W, Gosheger G: Primary multifocal osseous Hodgkin disease: a case report ... Bartl R, Frisch B, Burkhardt R, Huhn D, Pappenberger R: Assessment of bone marrow histology in Hodgkins disease: correlation ... Braunstein EM: Hodgkins disease of bone: radiographic correlation with the histological classification. Radiology 1980; 137: ...
Leukemia risk following Hodgkins disease: relation to cumulative dose of alkylating agents, treatment with teniposide ... Leukemia risk following Hodgkins disease: relation to cumulative dose of alkylating agents, treatment with teniposide ... Leukemia risk following Hodgkins disease: relation to cumulative dose of alkylating agents, treatment with teniposide ... Leukemia risk following Hodgkins disease: relation to cumulative dose of alkylating agents, treatment with teniposide ...
Hodgkin's Disease. 6 mg/m²/day IV q 1-2 week x 3-4week ... Hodgkin's Disease. 6 mg/m² q2week; part of combination ... Raynauds disease, varicose veins), heart disease (such as angina, heart attack), poor nutrition, liver disease, lung problems ... Caution in pulmonary disease, liver impairment, intestinal obstruction, paralytic ileus. Potential for jaw/parotid pain, ... Testicular CA, Squamous cell carcinoma CA of head & neck, Hodgkin's Dz, Kaposi's sarcoma; histiocytic lymphoma, ...
Hodgkins disease. Hydro-thorax. Hypochondriasis. Ichthyosis. Indigestion. Intermittent fever. Irritation. Jaundice. Kidney, ... Kidney, Brights disease of. Labia, inflammation of. Laryngitis. Lichen. Meningitis. Menstruation, derangements of. Nettle-rash ... Hip-joint disease. Hydrocele. Hydrocephalus. Hydrothorax. Hypochondriasis. Impotence. Influenza. Intermittents. Irritation. ... diseases of. Leucorrhoea. Lichen. Lips, eruption round.. Dulc , general. Adenitis. Angina faucium. Aphonia. Bladder, affections ...
Lymphomas: Hodgkins disease, non-Hodgkins lymphoma.. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and ... Improvement of Hodgkins disease and testicular tumors is prompt and noted within 2 weeks. If no improvement is seen by this ... Hodgkins Disease - 0.25 to 0.5 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or ... Squamous cell carcinoma, non-Hodgkins lymphoma, testicular carcinoma- 0.25 to 0.5 units/kg (10 to 20 units/m2) given ...
... we found-patients who experienced primary resistance or disease relapse (DR) had lower percentage of rosetted Hodgkin Reed- ... Using multiparametric flow cytometric analysis, in a cohort of 62 patients with classic Hodgkin lymphoma having a median follow ...
Hodgkins disease; Cyclophosphamide (Cytoxan) - multiple myeloma; breast, lung, and ovarian cancer; and, Carmustine (BiCNU) - ... The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. ... Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People ... Some of these antineoplastic agents are also being used for other purposes such as the treatment of nonmalignant diseases. ...
Neurological: Parkinsons disease, spinal cord injury, and stroke. Neoplastic: Hodgkins disease and myeloproliferative ... We also evaluate the efficacy of treatment using the HH Disease Severity Scale (HDSS). This scale consists of a simple and ... Secondary HH is due to an organic cause (such as endocrine and neurological diseases, substance use, menopause, neoplasia, or ... FH is a common disease and has a significant impact on patients quality of life. Clinical treatment with oxybutynin ...
The late 60s saw the development of two successful protocols for Hodgkins disease. The complete remission rate went from ... In comparison, heart disease deaths are a third of what they were then, thanks to innovations like statins, stents, and bypass ... Hodgkins lymphoma is now regarded as a curable affliction.. In the 1970s, chemotherapists expanded beyond lymphomas and ... In 2016, Facebook founder Mark Zuckerberg and his wife Priscilla Chan promised to spend $3 billion on "curing all disease in ...
Hodgkins disease. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. 2nd ed. New York: Oxford ... non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, Waldenstrom macroglobulinaemia and multiple myeloma (1 ). NHL is a heterogeneous ... Non-Hodgkin lymphoma in adults. In: Greer JP, Foerster J, Rodgers GM, et al., editors. Wintrobes Clinical hematology. 12th ed ... Non-Hodgkins lymphomas in Alexandria, Egypt; incidence rates and trend study (19952004). Eur J Cancer Prev. 2007 Oct;16(5):479 ...
  • Hodgkin disease (lymphoma) is a cancer of the lymph system that is characterized by the presence of large, abnormal Reed-Sternberg cells in a background of lymphocytes, macrophages, fibroblasts, and granulocytes. (medscape.com)
  • Classical Hodgkin lymphoma (HL) accounts for approximately 95% of all HL cases, with the other 5% being nodular lymphocyte-predominant HL (NLP-HL). (medscape.com)
  • Hodgkin lymphoma has an incidence of about 3 new cases per 100,000 individuals per year, making it one of the most common lymphomas. (medscape.com)
  • CT, MRI, PET/CT, and PET/MRI play a major role in the diagnosis, staging, and response to therapy of Hodgkin lymphoma. (medscape.com)
  • What is Hodgkin lymphoma? (medlineplus.gov)
  • Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system. (medlineplus.gov)
  • Hodgkin lymphoma is one of the main types of lymphoma . (medlineplus.gov)
  • The other is non-Hodgkin lymphoma. (medlineplus.gov)
  • What causes Hodgkin lymphoma? (medlineplus.gov)
  • The cause of Hodgkin lymphoma is unknown. (medlineplus.gov)
  • Who is more likely to develop Hodgkin lymphoma? (medlineplus.gov)
  • Hodgkin lymphoma is most common in early adulthood (age 20-39 years) and in late adulthood (age 65 years and older). (medlineplus.gov)
  • The risk of adult Hodgkin lymphoma is slightly higher in males than in females. (medlineplus.gov)
  • Having an infection with EBV as a young child or teenager increases your risk of Hodgkin lymphoma. (medlineplus.gov)
  • A family history of Hodgkin lymphoma. (medlineplus.gov)
  • Having a parent or sibling with Hodgkin lymphoma increases your risk of developing it. (medlineplus.gov)
  • What are the symptoms of Hodgkin lymphoma? (medlineplus.gov)
  • How is Hodgkin lymphoma diagnosed? (medlineplus.gov)
  • What are the treatments for Hodgkin lymphoma? (medlineplus.gov)
  • Hodgkin lymphoma can usually be cured if it is found and treated early. (medlineplus.gov)
  • After seeing doctor after doctor, I was diagnosed with Hodgkin lymphoma stage 3. (bmtinfonet.org)
  • My mom found a clinical trial at Memorial Sloan Kettering for patients with Hodgkin lymphoma. (bmtinfonet.org)
  • Nodular lymphocyte predominant Hodgkin lymphoma is an uncommon form of Hodgkin's lymphoma . (knowcancer.com)
  • Certain features of nodular lymphocyte predominant Hodgkin lymphoma distinguish it from other types of lymphoma. (knowcancer.com)
  • Approximately 8,000 Americans are diagnosed with Hodgkin lymphoma each year and about 5-10% of those are nodular lymphocyte predominant Hodgkin lymphoma cases. (knowcancer.com)
  • In approximately 3% of these cases the nodular lymphocyte predominant Hodgkin lymphoma goes beyond the lymph nodes and metastasizes into the bone marrow. (knowcancer.com)
  • The main symptom of nodular lymphocyte predominant Hodgkin lymphoma is enlarged lymph nodes. (knowcancer.com)
  • The cells of Nodular lymphocyte predominant Hodgkin lymphoma spread in an orderly fashion from one lymph node to another. (knowcancer.com)
  • A combination of chemotherapy and radiotherapy are generally used to treat nodular lymphocyte predominant Hodgkin lymphoma. (knowcancer.com)
  • Since nodular lymphocyte predominant Hodgkin lymphoma is often detected and diagnosed in the early stages prognosis is very good. (knowcancer.com)
  • We report a case of disseminated M. genavense infection preceding Hodgkin lymphoma in a patient without obvious risk factors for this infection. (cdc.gov)
  • Clinical manifestations and radiologic findings in the course of disease in a 23-year-old woman with disseminated M. genavense infection preceding Hodgkin lymphoma, Germany. (cdc.gov)
  • Seattle Genetics disclosed that the annual cost for Adcetris, which the FDA approved late last week to combat Hodgkin's disease and another rare lymphoma, will cost $13,500 per dose. (medicallessons.net)
  • Early clinical data suggest that patients who received Adcetris for Hodgkin lymphoma and systemic anaplastic lymphoma experienced a significant response to the therapy," said Richard Pazdur, M.D., in the late-Friday press release . (medicallessons.net)
  • Nursing Central , nursing.unboundmedicine.com/nursingcentral/view/Diseases-and-Disorders/73653/all/Lymphoma__Non_Hodgkin. (unboundmedicine.com)
  • Expression of MicroRNA-155 in Patients with Non-Hodgkin Lymphoma, Coronavirus Disease 2019, or Both: A Cross-Sectional Study. (bvsalud.org)
  • Non-Hodgkin lymphoma (NHL) is the eleventh leading cause of cancer -related death in the world. (bvsalud.org)
  • A Prospective Phase II Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients Aged 61 Years And Older, With Classical Hodgkin Lymphoma And Coexisting Medical Conditions. (clinicaltrials.gov)
  • ABSTRACT In view of the widespread use of pesticides in Egypt and the increasing incidence of leukaemia and lymphoma we aimed to assess pesticide exposure and other selected variables as risk factors for lymphoproliferative disorders (leukaemia and non-Hodgkin lymphoma). (who.int)
  • The risk was significant for cases of non-Hodgkin lymphoma but not chronic lymphocytic leukaemia. (who.int)
  • They are broadly classified into Hodgkin lymphoma and non-Hodgkin lymphoma. (sun-sentinel.com)
  • Specifically, these imaging exams have been validated for use only in Hodgkin lymphoma and in several forms of the most common types of non-Hodgkin lymphoma. (sun-sentinel.com)
  • In cases of lymphoma where PET scans are worthwhile, a scan typically is conducted before treatment begins to identify disease stage. (sun-sentinel.com)
  • For example, a patient with Hodgkin lymphoma may have a mass develop as part of the disease. (sun-sentinel.com)
  • Velban is a prescription medication used to treat a variety of cancers including Hodgkin's disease, lymphoma, breast cancer, testicular cancer , and a certain type of uterine cancer . (rxwiki.com)
  • Lymphosarcoma does not included Hodgkin's disease, and is therefore, also referred to as non-Hodgkin's lymphoma. (cdc.gov)
  • non-Hodgkin lymphoma, other and unspecified types (C85. (who.int)
  • en la variante de predominio linfocítico, nodular, se ven linfocitos e histiocitos. (bvsalud.org)
  • A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. (bvsalud.org)
  • Centers for Disease Control and Prevention. (cdc.gov)
  • The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. (cdc.gov)
  • I was among the 15 percent of patients with this disease for whom chemo, alone, didn't work. (bmtinfonet.org)
  • Mycobacterium genavense infection, a rare nontuberculous mycobacteria infection, occurs in heavily immunocompromised patients (i.e., those with advanced HIV disease, genetic disorders, or acquired immunologic disorders and those undergoing immunosuppressive therapy). (cdc.gov)
  • Mycobacterium genavense was first described in 1992 in HIV-positive patients with low CD4 counts and disseminated mycobacterial disease ( 1 ). (cdc.gov)
  • EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S) cells of about 40% of patients with Hodgkin's Disease (HD) provide targets for immunotherapy with virus-specific cytotoxic T lymphocytes (CTL). (houstonmethodist.org)
  • Between 1972 and 1994, 121 adult patients with advanced Hodgkin's disease received MOPP (M) combination chemotherapy, MOPP alternating with ABVD (M-A) or MOPP and ABV hybrid (M/A). Radiation therapy was given to 1/3 of them. (haifa.ac.il)
  • Today, 80% of patients with advanced Hodgkin's disease may be cured, with low rate of long-term toxicity. (haifa.ac.il)
  • In case of progressive disease, according to Lugano Classification (Cheson et al.2014, PET-CT scan based response) patients will be considered in treatment failure. (clinicaltrials.gov)
  • In case of progressive disease , patients will be considered in treatment failure. (clinicaltrials.gov)
  • Patients with t-AML should be enrolled on front-line chemotherapy trials, appropriate for de novo AML patients with similar disease characteristics. (nih.gov)
  • Patients whose disease goes into remission after three rounds of chemotherapy are most likely to stay in remission the longest, and that provides valuable information to guide additional treatment. (sun-sentinel.com)
  • The license for adult use was granted under FDA's accelerated approval pathway, which allows the agency to approve products for serious or life-threatening diseases on the basis of early evidence of a product's effectiveness that is reasonably likely to predict clinical benefit. (cdc.gov)
  • Positron emission tomography (PET) scanning with fluorodeoxyglucose (FDG) is most useful for detecting disease relapse. (medscape.com)
  • Up to winter 2021-2022, the death toll caused by the coronavirus disease 2019 (COVID-19) has exceeded 5.6 million worldwide. (bvsalud.org)
  • FDG/PET and MRI can identify involvement of bone marrow, and imaging can confirm poor prognostic indicators such as large mediastinal adenopathy, stage IV disease, systemic symptoms, and pleural effusion and pericardial effusion. (medscape.com)
  • Bone scanning is useful for evaluating bone involvement in Hodgkin disease. (medscape.com)
  • The last step before my bone marrow transplant would be radiation to get rid of the remaining disease. (bmtinfonet.org)
  • Clinically, CTL produced resolution of B symptoms and mixed tumor responses including one complete remission of residual disease remaining after autologous bone marrow transplant. (houstonmethodist.org)
  • Clinicians generally classify the disease based on whether it predominantly affects the skin, in which case it tends to be indolent, or if it affects internal organs like the bone marrow, liver and brain, in which case it tends to be aggressive and be unresponsive to standard chemo regimens like CHOP . (medicallessons.net)
  • The reason to perform an interim scan after three rounds of chemotherapy is to find out if the disease has gone into remission. (sun-sentinel.com)
  • He or she can undergo chemotherapy that puts the disease into remission, but a portion of the mass that's not cancerous might remain behind. (sun-sentinel.com)
  • ORRHES) requested that the Agency for Toxic Substances and Disease Registry (ATSDR) and the Tennessee Cancer Registry (TCR) of the Tennessee Department of Health assess the incidence of cancer in this area. (cdc.gov)
  • However, Hodgkin tumors use multiple strategies to avoid CTL, including down-regulation of immunodominant EBV antigens, and secretion of cytokines and chemokines such as TGF-β, that inhibit the activation of CTL and professional antigen-presenting cells (APC). (houstonmethodist.org)
  • Future clinical studies will test the efficacy of CTL with improved antigen-specificity and resistance to Hodgkin immune evasion strategies. (houstonmethodist.org)
  • In some cases the treatment can cause more harm than the disease itself. (knowcancer.com)
  • For this nontuberculous mycobacteria (NTM) disease, diagnostic criteria are ill defined and no treatment guidelines are established. (cdc.gov)
  • Some of these antineoplastic agents are also being used for other purposes such as the treatment of nonmalignant diseases. (cdc.gov)
  • If the disease is not in remission, at that point, the treatment plan likely needs to change to combat the disease more effectively. (sun-sentinel.com)
  • The incidence of invasive disease ranges from 3.8 per 100,000 among persons aged 18-34 years to 36.4 per 100,000 among those aged ≥65 years ( 4 ). (cdc.gov)
  • However, no complete remission of bulky disease was achieved. (houstonmethodist.org)
  • Now if a PET scan shows no activity, but a lump is still there, it's safe to assume the disease is in remission and the mass is benign, so a biopsy isn't necessary. (sun-sentinel.com)
  • 51 disease terms (MeSH) has been reported with MYB gene. (cdc.gov)
  • effective than conventional drugs in targeting disease. (who.int)
  • The median age was 35 years, 58% had stage III and 42% had stage IV disease. (haifa.ac.il)
  • The proportion of SCR and DR subsets did not differ by histological subtypes, disease stage or age groups. (bmj.com)
  • Gallium-67 ( 67 Ga) scans obtained at baseline, during therapy, and in the posttreatment period can help differente active Hodgkin disease from nonactive Hodgkin disease. (medscape.com)
  • Adults with certain medical conditions also are at increased risk for invasive pneumococcal disease (IPD). (cdc.gov)
  • The disease rates for adults in these groups can be more than 20 times those for adults without high-risk medical conditions. (cdc.gov)
  • This will include checking for signs of disease, such as lumps or anything else that seems unusual. (medlineplus.gov)
  • Mediastinal adenopathy is the most common presentation, and direct extension of the disease can be detected on chest radiographs. (medscape.com)
  • certain localized infections - see body system-related chapters infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium [except obstetrical tetanus] (O98. (who.int)
  • Since then, we have spent nearly $200 billion in federal money on research to defeat the disease. (reason.com)
  • The Agency for Toxic Substances and Disease Registry (ATSDR), a public health agency of the U.S. Department of Health and Human Services, has issued the final version of its public health assessment on the Lawrence Livermore National Laboratory Main Site (LLNL), Livermore, Calif. The lab is operated by the University of California for the U.S. Department of Energy. (cdc.gov)
  • Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. (cdc.gov)
  • CDHS prepared the report under a cooperative agreement with the federal Agency for Toxic Substances and Disease Registry (ATSDR), part of the U.S. Department of Health and Human Services. (cdc.gov)
  • The Agency for Toxic Substances and Disease Registry (ATSDR) will hold a community meeting Aug.11 to discuss its findings from the public health assessment conducted on the Lawrence Livermore National Lab site (LLNL). (cdc.gov)

No images available that match "hodgkin disease"